Tetra Bio-Pharma Inc. - TBPMF STOCK NEWS

Tetra Bio-Pharma announced promising results for its investigational drug ARDS-003 in reducing inflammation in a lung injury model. The pre-clinical studies demonstrated a decrease in inflammatory cytokine markers and fibrosis in lung tissue. These findings suggest the potential of ARDS-003 as a treatment for severe inflammatory disorders, including those associated with COVID-19. The company plans to submit an application for a Phase I clinical trial to assess the drug's safety and pharmacokinetics in healthy volunteers.

Tetra Bio-Pharma Inc. plans to submit a marketing application for a Dronabinol soft gel capsule in Q4 2020 to gain a Drug Identification Number (DIN). The company expects approval in the first half of 2021. Dronabinol's previous withdrawal from the Canadian market was due to quality issues, not sales volume. The global market for chemotherapy-induced nausea and vomiting (CINV) is valued at $2.6 billion. Tetra is also developing a second proprietary THC drug and a third inhaled THC formulation to enhance its product portfolio.

Tetra Bio-Pharma, a leader in cannabinoid drug development, will present at the Alpha Bronze Virtual Town Hall on October 7, 2020, at 12:00 PM EDT. CEO Dr. Guy Chamberland will discuss the company’s pipeline, highlighting its lead program, ARDS-003, and its recent acquisition of Canadian Distribution Rights for Dronabinol Soft Gel Capsules. The presentation will include a Q&A session for investors. Register for the live webcast.

Tetra Bio-Pharma announced a definitive agreement to acquire exclusive Canadian rights for Dronabinol Soft Gel capsules. This acquisition is part of Tetra's strategy to establish a commercial presence in Canada and expedite its first New Drug Submission for a THC-based prescription drug, CAUMZ^TM. The Dronabinol drug is aimed at treating chemotherapy-induced nausea and vomiting, with an addressable market projected to be $80 million by 2022. The acquisition will enable Tetra to generate immediate revenue and contribute significantly to profitability goals.

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) announced key management changes to strengthen its leadership team. Ms. Dale Weil and Dr. Brent Norton joined the Board of Directors, while Dr. Graham Wood has been appointed as Chief Operating Officer, succeeding Steeve Neron, who will now serve as Chief Commercial Officer. These appointments bring extensive experience from pharmaceutical and biotechnology sectors, expected to enhance Tetra's capabilities in clinical drug development and commercialization. The company aims to leverage these new leaders to advance its clinical assets and achieve its next growth phase.

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announces the appointment of Jean-Francois Boily as Chief Financial Officer, effective September 14. He replaces Sabino Di Paola, who played a crucial role in financing Tetra's clinical operations and transitioning from TSXV to TSX. Boily brings over 15 years of experience in clinical research and pharmaceuticals, aiming to bolster Tetra's growth strategy. CEO Dr. Guy Chamberland praised Boily's extensive expertise, highlighting its importance in Tetra's ambitions for future expansion and success in the biopharmaceutical industry.

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) has appointed Dania Scott as the Senior Vice President of Commercial Strategy, responsible for the global commercialization of QIXLEEF™. With over 20 years of experience in the pharmaceutical and cannabis sectors, Scott previously held roles at Canopy Growth Corporation and Shoppers Drug Mart. CEO Dr. Guy Chamberland emphasizes her skills will aid the commercialization of QIXLEEF™ across various regions. Tetra recently completed financing to advance QIXLEEF™, which is supported by a clinical trial aimed at establishing its efficacy.

Tetra Bio-Pharma has initiated the clinical trial operations for its investigational drug QIXLEEF™, aimed at alleviating pain in cancer patients. The Plenitude® trial has received all necessary authorizations from the FDA and DEA, and involves ten clinical sites across the US. This double-blind, placebo-controlled trial will enroll 78 patients and aims to demonstrate the safety and efficacy of inhaled QIXLEEF™. CEO Dr. Guy Chamberland expressed confidence in the trial's safety following recent data showing reduced CBD metabolite levels, addressing previous concerns about liver injury.

Tetra Bio-Pharma has announced the successful mapping of CBD metabolites in humans after vaporization of QIXLEEF™, a therapy for uncontrolled pain in cancer patients. This study is crucial for regulatory approvals from the FDA and Health Canada. Findings indicated that the inhalation method results in lower levels of harmful metabolites, promoting a safety advantage over oral intake. The data suggest that QIXLEEF™ achieves rapid absorption and efficacy with fewer side effects, positioning it as a preferable option for patients in need of pain relief.